Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Correlations between intratumoral vascular network and tumoral architecture in prostatic adenocarcinoma.

Pleşea IE, Stoiculescu A, Serbănescu M, Alexandru DO, Man M, Pop OT, Pleşea RM.

Rom J Morphol Embryol. 2013;54(2):299-308.

2.

Correlations between intratumoral interstitial fibrillary network and tumoral architecture in prostatic adenocarcinoma.

Stoiculescu A, Pleşea IE, Pop OT, Alexandru DO, Man M, Serbănescu M, Pleşea RM.

Rom J Morphol Embryol. 2012;53(4):941-50.

3.

Correlations between intratumoral interstitial fibrillary network and vascular network in Srigley patterns of prostate adenocarcinoma.

Mitroi G, Pleşea RM, Pop OT, Ciovică DV, Şerbănescu MS, Alexandru DO, Stoiculescu A, Pleşea IE.

Rom J Morphol Embryol. 2015;56(4):1319-28.

4.

High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.

Zhao J, Epstein JI.

Am J Surg Pathol. 2009 Apr;33(4):583-90. doi: 10.1097/PAS.0b013e31818a5c6c.

PMID:
19033862
5.
6.

Prostatic adenocarcinoma with glomeruloid features.

Pacelli A, Lopez-Beltran A, Egan AJ, Bostwick DG.

Hum Pathol. 1998 May;29(5):543-6.

PMID:
9596281
8.

Small cell-like change in prostatic intraepithelial neoplasia, intraductal carcinoma, and invasive prostatic carcinoma: a study of 7 cases.

Lee S, Han JS, Chang A, Ross HM, Montironi R, Yorukoglu K, Lane Z, Epstein JI.

Hum Pathol. 2013 Mar;44(3):427-31. doi: 10.1016/j.humpath.2012.06.008. Epub 2012 Sep 29.

PMID:
23026197
9.

Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.

Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G.

Prostate. 2000 Sep 15;45(1):72-9.

PMID:
10960845
10.

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW.

J Urol. 1998 Aug;160(2):459-65.

PMID:
9679898
11.

Prostatic adenocarcinoma with Paneth cell-like change.

Kuroda N, Katto K, Shiotsu T, Lee GH.

APMIS. 2007 Jul;115(7):857-8. No abstract available.

PMID:
17614853
12.

Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.

Shah RB, Magi-Galluzzi C, Han B, Zhou M.

Am J Surg Pathol. 2010 Apr;34(4):470-7. doi: 10.1097/PAS.0b013e3181cfc44b.

PMID:
20182345
13.

[Histopathology reports of findings of prostate needle biopsies. Individual treatment].

Damjanoski I, Müller J, Schnöller TJ, Küfer R, Rinnab L.

Urologe A. 2013 Feb;52(2):226-39. doi: 10.1007/s00120-012-3008-1. German. Retraction in: Urologe A. 2017 Aug 28;:.

PMID:
23064867
14.

Tumor neoangiogenesis in rebiopsied patients with prostatic carcinoma.

Volavsek M, Masera A, Ovcak Z.

Acta Med Croatica. 1999;53(2):73-8.

PMID:
10705624
15.

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation.

Montironi R, Magi-Galluzzi C, Fabris G.

Pathol Res Pract. 1995 Sep;191(9):873-80.

PMID:
8606868
16.

Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.

Sinha AA, Gleason DF, Staley NA, Wilson MJ, Sameni M, Sloane BF.

Anat Rec. 1995 Mar;241(3):353-62.

PMID:
7538734
17.

High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.

Tavora F, Epstein JI.

Am J Surg Pathol. 2008 Jul;32(7):1060-7. doi: 10.1097/PAS.0b013e318160edaf.

PMID:
18496142
18.

Assessment of Gleason system use on different types of prostatic tissue samples.

Pleşea IE, Zaharia B, Enache SD, Mitroi G, Tomescu P, Pop OT, Badea P, Kozokić A.

Rom J Morphol Embryol. 1999-2004;45:25-34.

PMID:
15847376
19.

Primary prostatic central zone adenocarcinoma.

Mai KT, Belanger EC, Al-Maghrabi HM, Robertson S, Wang D, Margnean C.

Pathol Res Pract. 2008;204(4):251-8. doi: 10.1016/j.prp.2007.11.002. Epub 2008 Jan 4.

PMID:
18178014
20.

Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.

Iczkowski KA, Pantazis CG, McGregor DH, Wu Y, Tawfik OW.

Cancer. 2002 Dec 15;95(12):2487-93.

Supplemental Content

Support Center